Dec 30 2009
Meda (STO:MEDAA) expands the collaboration with the French development
company Etypharm for the patented product Axorid. New territories, such
as East Europe with Russia and Turkey, are now included in the
collaboration. Previously, Meda held commercialization rights in Central
and West Europe.
Axorid consists of the well-known and broadly used substances;
ketoprofen, a NSAID (Non Sterodial Anti-Inflammatory Drug) for the
treatment of rheumatic disorders, and omeprazole, an acid reducing
proton pump inhibitor (PPI). Axorid can prevent gastrointestinal side
effects from use of NSAIDs. Axorid’s once-daily administration can also
increase patient compliance.
http://www.cisionwire.com